Loading stock data…
TARS
$63.62+0.01 (+0.02%)
Market ClosedLast close May 1
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $63.62. The stock is currently 25% below its 52-week high of $85.25, remaining 3.8% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why TARS maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$63.62
Potential Upside
5%
Whystock Fair Value$66.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$94.22+48.1%
Range$88.00 – $100.00
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.70B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.44%
Volume
Today's trading volume
538,318
Recent News
Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates
Amgen (AMGN) delivered earnings and revenue surprises of +8.87% and +1.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses
Recent performance and business snapshot Tarsus Pharmaceuticals (TARS) has attracted fresh attention after recent trading, with the stock closing at US$70.12 and showing mixed share price moves over the past week, month and past 3 months. The company focuses on eye care therapies in the United States, with commercial revenue of US$451.36 million and a reported net loss of US$66.418 million. This puts profitability and growth plans in clear focus for investors. See our latest analysis for...
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors
Tarsus Pharmaceuticals recently dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic U.S. regions. This program targets a large unmet need as a potential first-in-class, non-vaccine, drug-based prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. We’ll now examine how TP-05’s Phase 2 progress, building on earlier “tick kill”...
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score.
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade
This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye diseases.